Delayed melatonin administration promotes neuronal survival, neurogenesis and motor recovery, and attenuates hyperactivity and anxiety after mild focal cerebral ischemia in mice

Abstract:  Melatonin is a potent antioxidant with neuroprotective activity in animal models of ischemic stroke, which based on its lack of serious toxicity has raised hopes that it might be used for human stroke treatment in the future. This study investigated how subacute delivery of melatonin, starting at 24 hr after stroke onset, and continuing for 29 days (4 mg/kg/day; via drinking water), influences neuronal survival, endogenous neurogenesis, motor recovery and locomotor activity in C57Bl6/j mice submitted to 30‐min middle cerebral artery occlusion. Histologic studies showed that melatonin improved neuronal survival and enhanced neurogenesis, even when applied 1 day after stroke. Cell survival was associated with a long‐lasting improvement of motor and coordination deficits, evaluated by the grip strength and RotaRod tests, as well as with attenuation of hyperactivity and anxiety of the animals as revealed in open field tests. The robust functional neurologic improvements encourage proof‐of‐concept studies with melatonin in human stroke patients.

[1]  D. Hermann,et al.  Neuroprotection in the SAINT‐II aftermath , 2007, Annals of neurology.

[2]  D. Hermann,et al.  Tissue plasminogen activator-induced reperfusion injury after stroke revisited. , 2007, Circulation.

[3]  M. Ginsberg.  Life After Cerovive: A Personal Perspective on Ischemic Neuroprotection in the Post–NXY-059 Era , 2007, Stroke.

[4]  K. Manda,et al.  AFMK, a melatonin metabolite, attenuates X‐ray‐induced oxidative damage to DNA, proteins and lipids in mice , 2007, Journal of pineal research.

[5]  T. Moriya,et al.  Melatonin influences the proliferative and differentiative activity of neural stem cells , 2007, Journal of pineal research.

[6]  M. Fisher,et al.  Future of neuroprotection for acute stroke: In the aftermath of the SAINT trials , 2007, Annals of neurology.

[7]  D. Hermann,et al.  Implications of ATP-binding cassette transporters for brain pharmacotherapies. , 2007, Trends in pharmacological sciences.

[8]  R. Reiter,et al.  One molecule, many derivatives: A never‐ending interaction of melatonin with reactive oxygen and nitrogen species? , 2007, Journal of pineal research.

[9]  S. Tam,et al.  Preclinical evaluation of pharmacokinetics and safety of melatonin in propylene glycol for intravenous administration , 2006, Journal of pineal research.

[10]  Li Huang,et al.  Melatonin reduces infarction volume in a photothrombotic stroke model in the wild‐type but not cyclooxygenase‐1‐gene knockout mice , 2006, Journal of pineal research.

[11]  E. Kılıç,et al.  The phosphatidylinositol‐3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  G. Donnan,et al.  1,026 Experimental treatments in acute stroke , 2006, Annals of neurology.

[13]  H. Lipp,et al.  Reduced locomotion in the serum and glucocorticoid inducible kinase 3 knock out mouse , 2006, Behavioural Brain Research.

[14]  T. Palmer,et al.  Neurogenesis in Rats After Focal Cerebral Ischemia is Enhanced by Indomethacin , 2005, Stroke.

[15]  M. Gassmann,et al.  Brain‐derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK‐1/‐2 and Akt pathways , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  M. Chopp,et al.  Multitargeted Effects of Statin-Enhanced Thrombolytic Therapy for Stroke With Recombinant Human Tissue-Type Plasminogen Activator in the Rat , 2005, Circulation.

[17]  G. Juckel,et al.  Anxious and Hyperactive Phenotype Following Brief Ischemic Episodes in Mice , 2005, Biological Psychiatry.

[18]  M. Hori,et al.  Adenovirus-Mediated Gene Transfer of Heparin-Binding Epidermal Growth Factor-Like Growth Factor Enhances Neurogenesis and Angiogenesis After Focal Cerebral Ischemia in Rats , 2005, Stroke.

[19]  E. Kılıç,et al.  Tissue‐plasminogen activator‐induced ischemic brain injury is reversed by melatonin: role of iNOS and Akt , 2005, Journal of pineal research.

[20]  E. Kılıç,et al.  When Melatonin Gets on Your Nerves: Its Beneficial Actions in Experimental Models of Stroke , 2005, Experimental biology and medicine.

[21]  T. Lüscher,et al.  Aggravation of Focal Cerebral Ischemia by Tissue Plasminogen Activator Is Reversed by 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor but Does Not Depend on Endothelial NO Synthase , 2005, Stroke.

[22]  G. Donnan,et al.  Systematic review and meta‐analysis of the efficacy of melatonin in experimental stroke , 2005, Journal of pineal research.

[23]  E. Kılıç,et al.  Signal transduction pathways involved in melatonin‐induced neuroprotection after focal cerebral ischemia in mice , 2005, Journal of pineal research.

[24]  Claudio L Bassetti,et al.  VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena. , 2004, Brain : a journal of neurology.

[25]  E. Kılıç,et al.  Prophylactic use of melatonin protects against focal cerebral ischemia in mice: role of endothelin converting enzyme‐1 , 2004, Journal of pineal research.

[26]  R. Cheung,et al.  Pretreatment with melatonin exerts anti‐inflammatory effects against ischemia/reperfusion injury in a rat middle cerebral artery occlusion stroke model , 2004, Journal of pineal research.

[27]  S. Yim,et al.  Melatonin increases cell proliferation in the dentate gyrus of maternally separated rats , 2004, Journal of pineal research.

[28]  T. Peng,et al.  Visualization of the antioxidative effects of melatonin at the mitochondrial level during oxidative stress‐induced apoptosis of rat brain astrocytes , 2004, Journal of pineal research.

[29]  I. Sayeed,et al.  Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti‐apoptotic effects of melatonin , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  E. Kılıç,et al.  Melatonin reduces disseminate neuronal death after mild focal ischemia in mice via inhibition of caspase‐3 and is suitable as an add‐on treatment to tissue‐plasminogen activator , 2004, Journal of pineal research.

[31]  Scott Hamilton,et al.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , 2004, The Lancet.

[32]  Jürgen Winkler,et al.  Transient expression of doublecortin during adult neurogenesis , 2003, The Journal of comparative neurology.

[33]  A. Akhmedov,et al.  Impaired explorative behavior and neophobia in genetically modified mice lacking or overexpressing the extracellular serine protease inhibitor neuroserpin , 2003, Molecular and Cellular Neuroscience.

[34]  R. Cheung.  The utility of melatonin in reducing cerebral damage resulting from ischemia and reperfusion , 2003, Journal of pineal research.

[35]  R. Cheung,et al.  Melatonin reduces nitric oxide level during ischemia but not blood–brain barrier breakdown during reperfusion in a rat middle cerebral artery occlusion stroke model , 2003, Journal of pineal research.

[36]  S. Pang,et al.  Administration of Melatonin After Onset of Ischemia Reduces the Volume of Cerebral Infarction in a Rat Middle Cerebral Artery Occlusion Stroke Model , 2003, Stroke.

[37]  R. Reiter,et al.  Melatonin: detoxification of oxygen and nitrogen-based toxic reactants. , 2003, Advances in experimental medicine and biology.

[38]  Jin Gu,et al.  Neuroprotection by melatonin against ischemic neuronal injury associated with modulation of DNA damage and repair in the rat following a transient cerebral ischemia , 2002, Journal of pineal research.

[39]  S. Pang,et al.  Pretreatment with melatonin reduces volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model , 2002, Journal of pineal research.

[40]  S. Cuzzocrea,et al.  Effects of Melatonin Treatment in Septic Newborns , 2001, Pediatric Research.

[41]  Hans-Peter Lipp,et al.  Extended analysis of path data from mutant mice using the public domain software Wintrack , 2001, Physiology & Behavior.

[42]  S. Kügler,et al.  Adenovirus-Mediated GDNF and CNTF Pretreatment Protects against Striatal Injury Following Transient Middle Cerebral Artery Occlusion in Mice , 2001, Neurobiology of Disease.

[43]  G. Mies,et al.  Relationship between metabolic dysfunctions, gene responses and delayed cell death after mild focal cerebral ischemia in mice , 2001, Neuroscience.

[44]  E. Mazzon,et al.  Protective effects of melatonin in ischemic brain injury , 2000, Journal of pineal research.

[45]  Stroke Therapy Academic Industry Roundtable.  Recommendations for standards regarding preclinical neuroprotective and restorative drug development. , 1999, Stroke.

[46]  H. Bolay,et al.  Pinealectomy Aggravates and Melatonin Administration Attenuates Brain Damage in Focal Ischemia , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[47]  David P. Wolfer,et al.  Neurobehavioral development, adult openfield exploration and swimming navigation learning in mice with a modified β-amyloid precursor protein gene , 1998, Behavioural Brain Research.

[48]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[49]  S. Papson,et al.  “Model” , 1981 .